Sunday, 15 July 2012

Loestrin 1/20



norethindrone acetate and ethinyl estradiol

Dosage Form: tablet
LOESTRIN® 21 Day

(norethindrone acetate and ethinyl estradiol tablets, USP)

LOESTRIN® Fe 28 Day

(norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets*)

*Ferrous fumarate tablets are not USP for dissolution and assay.

LOESTRIN®  21 Day


(norethindrone acetate and ethinyl estradiol tablets, USP)


LOESTRIN® 1/20


(Each light yellow tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol.)


LOESTRIN® 1.5/30


(Each pink tablet contains 1.5 mg norethindrone acetate and 30 mcg ethinyl estradiol.)


LOESTRIN® Fe 28 Day


(norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets*)


*Ferrous fumarate tablets are not USP for dissolution and assay


LOESTRIN®  Fe 1/20


(Each light yellow tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol. Each brown tablet contains 75 mg ferrous fumarate.)


LOESTRIN®  Fe 1.5/30


(Each pink tablet contains 1.5 mg norethindrone acetate and 30 mcg ethinyl estradiol. Each brown tablet contains 75 mg ferrous fumarate.)


Rx only


Patients should be counseled that this product does not protect against HIV infections (AIDS) and other sexually transmitted diseases.



Loestrin 1/20 Description


LOESTRIN  21 and LOESTRIN  Fe 28  are progestogen-estrogen combinations.


LOESTRIN  Fe 1/20 and 1.5/30: Each provides a continuous dosage regimen consisting of 21 oral contraceptive tablets and seven ferrous fumarate tablets. The ferrous fumarate tablets are present to facilitate ease of drug administration via a 28-day regimen, are non-hormonal, and do not serve any therapeutic purpose.


Each light yellow tablet contains norethindrone acetate (17α-ethinyl-19-nortestosterone acetate), 1 mg; ethinyl estradiol (17α-ethinyl-1,3,5(10)-estratriene-3, 17β-diol), 20 mcg. Each light yellow tablet contains the following inactive ingredients: acacia, compressible sugar, D&C yellow no. 10 aluminum lake, lactose monohydrate, magnesium stearate and pregelatinized starch.


Each pink tablet contains norethindrone acetate (17α-ethinyl-19-nortestosterone acetate), 1.5 mg; ethinyl estradiol (17α-ethinyl-1,3,5(10)-estratriene-3, 17β-diol), 30 mcg. Each pink tablet contains the following inactive ingredients: acacia, compressible sugar, FD&C red no. 40 aluminum lake HT, lactose monohydrate, magnesium stearate and pregelatinized starch.


Each brown tablet contains the following ingredients: crospovidone, ferrous fumarate, hydrogenated vegetable oil, NF Type I and microcrystalline cellulose.


C22H28O3 Molecular Weight: 340.46



C20H24O2 Molecular Weight: 296.40




Loestrin 1/20 - Clinical Pharmacology


Combination oral contraceptives act by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which reduce the likelihood of implantation).



Pharmacokinetics


The pharmacokinetics of norethindrone acetate and ethinyl estradiol tablets have not been characterized; however, the following pharmacokinetic information regarding norethindrone acetate and ethinyl estradiol is taken from the literature.



Absorption


Norethindrone acetate appears to be completely and rapidly deacetylated to norethindrone after oral administration, since the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone (1). Norethindrone acetate and ethinyl estradiol are subject to first-pass metabolism after oral dosing, resulting in an absolute bioavailability of approximately 64% for norethindrone and 43% for ethinyl estradiol (1-3).



Distribution


Volume of distribution of norethindrone and ethinyl estradiol ranges from 2 to 4 L/kg (1-3). Plasma protein binding of both steroids is extensive (>95%); norethindrone binds to both albumin and sex hormone binding globulin, whereas ethinyl estradiol binds only to albumin (4).



Metabolism


Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites (5). A small amount of norethindrone acetate is metabolically converted to ethinyl estradiol. Ethinyl estradiol is also extensively metabolized, both by oxidation and by conjugation with sulfate and glucuronide. Sulfates are the major circulating conjugates of ethinyl estradiol and glucuronides predominate in urine.


The primary oxidative metabolite is 2-hydroxy ethinyl estradiol, formed by the CYP3A4 isoform of cytochrome P450. Part of the first-pass metabolism of ethinyl estradiol is believed to occur in gastrointestinal mucosa. Ethinyl estradiol may undergo enterohepatic circulation (6).



Excretion


Norethindrone and ethinyl estradiol are excreted in both urine and feces, primarily as metabolites (5,6). Plasma clearance values for norethindrone and ethinyl estradiol are similar (approximately 0.4 L/hr/kg) (1-3).



Special Population


Race

The effect of race on the disposition of norethindrone acetate and ethinyl estradiol tablets has not been evaluated.


Renal Insufficiency

The effect of renal disease on the disposition of norethindrone acetate and ethinyl estradiol tablets has not been evaluated. In premenopausal women with chronic renal failure undergoing peritoneal dialysis who received multiple doses of an oral contraceptive containing ethinyl estradiol and norethindrone, plasma ethinyl estradiol concentrations were higher and norethindrone concentrations were unchanged compared to concentrations in premenopausal women with normal renal function.


Hepatic Insufficiency

The effect of hepatic disease on the disposition of norethindrone acetate and ethinyl estradiol tablets has not been evaluated. However, ethinyl estradiol and norethindrone may be poorly metabolized in patients with impaired liver function.



Drug-Drug Interactions


Numerous drug-drug interactions have been reported for oral contraceptives. A summary of these is found under PRECAUTIONS, Drug Interactions.



Indications and Usage for Loestrin 1/20


LOESTRIN  21 and LOESTRIN  Fe 28  are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.


Oral contraceptives are highly effective. Table I lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates.




















































TABLE I LOWEST EXPECTED AND TYPICAL FAILURE RATES DURING THE FIRST YEAR OF CONTINUOUS USE OF A METHOD
Adapted from RA Hatcher et al, Reference 7.

*

The authors' best guess of the percentage of women expected to experience an accidental pregnancy among couples who initiate a method (not necessarily for the first time) and who use it consistently and correctly during the first year if they do not stop for any other reason.

†

This term represents “typical” couples who initiate use of a method (not necessarily for the first time), who experience an accidental pregnancy during the first year if they do not stop use for any other reason.

‡

N/A--Data not available.

% of Women Experiencing an Unintended Pregnancy

in the First Year of Continuous Use
MethodLowest

Expected*
Typical†
(No contraception)(85)(85)
Oral contraceptives

combined

progestin only


0.1

0.5
3

N/A‡

N/A‡
Diaphragm with spermicidal

cream or jelly


6


20
Spermicides alone (foam, creams,

gels, vaginal suppositories,

and vaginal film)



6



26
Vaginal Sponge

nulliparous

parous


9

20


20

40
Implant0.050.05
Injection: depot medroxyprogesterone

acetate


0.3


0.3
IUD

progesterone T

copper T 380A

LNg 20


1.5

0.6

0.1


2.0

0.8

0.1
Condom without spermicides

female

male


5

3


21

14
Cervical Cap with spermicidal

cream or jelly

nulliparous

parous



9

26



20

40
Periodic abstinence (all methods)1-925
Withdrawal419
Female sterilization0.50.5
Male sterilization0.100.15

Contraindications


Oral contraceptives should not be used in women who currently have the following conditions:


  • Thrombophlebitis or thromboembolic disorders

  • A past history of deep vein thrombophlebitis or thromboembolic disorders

  • Cerebral vascular or coronary artery disease

  • Known or suspected carcinoma of the breast

  • Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia

  • Undiagnosed abnormal genital bleeding

  • Cholestatic jaundice of pregnancy or jaundice with prior pill use

  • Hepatic adenomas or carcinomas

  • Known or suspected pregnancy


Warnings




Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke.




The use of oral contraceptives is associated with increased risks of several serious conditions including myocardial infarction, thromboembolism, stroke, hepatic neoplasia, and gallbladder disease, although the risk of serious morbidity or mortality is very small in healthy women without underlying risk factors. The risk of morbidity and mortality increases significantly in the presence of other underlying risk factors such as hypertension, hyperlipidemias, obesity, and diabetes.


Practitioners prescribing oral contraceptives should be familiar with the following information relating to these risks.


The information contained in this package insert is principally based on studies carried out in patients who used oral contraceptives with higher formulations of estrogens and progestogens than those in common use today. The effect of long-term use of the oral contraceptives with lower formulations of both estrogens and progestogens remains to be determined.


Throughout this labeling, epidemiological studies reported are of two types: retrospective or case control studies and prospective or cohort studies. Case control studies provide a measure of the relative risk of a disease, namely, a ratio of the incidence of a disease among oral contraceptive users to that among nonusers. The relative risk does not provide information on the actual clinical occurrence of a disease.


Cohort studies provide a measure of attributable risk, which is the difference in the incidence of disease between oral contraceptive users and nonusers. The attributable risk does provide information about the actual occurrence of a disease in the population (adapted from References 8 and 9 with the author's permission). For further information, the reader is referred to a text on epidemiological methods.



1. Thromboembolic Disorders and Other Vascular Problems


a. Myocardial Infarction

An increased risk of myocardial infarction has been attributed to oral contraceptive use. This risk is primarily in smokers or women with other underlying risk factors for coronary artery disease such as hypertension, hypercholesterolemia, morbid obesity, and diabetes. The relative risk of heart attack for current oral contraceptive users has been estimated to be two to six (10-16). The risk is very low under the age of 30.


Smoking in combination with oral contraceptive use has been shown to contribute substantially to the incidence of myocardial infarctions in women in their mid-thirties or older with smoking accounting for the majority of excess cases (17). Mortality rates associated with circulatory disease have been shown to increase substantially in smokers over the age of 35 and non-smokers over the age of 40 (Table II) among women who use oral contraceptives.


TABLE II CIRCULATORY DISEASE MORTALITY RATES PER 100,000 WOMAN YEARS BY AGE, SMOKING STATUS AND ORAL CONTRACEPTIVE USE Adapted from P.M. Layde and V. Beral, Reference 18



Oral contraceptives may compound the effects of well-known risk factors, such as hypertension, diabetes, hyperlipidemias, age and obesity (19). In particular, some progestogens are known to decrease HDL cholesterol and cause glucose intolerance, while estrogens may create a state of hyperinsulinism (20-24). Oral contraceptives have been shown to increase blood pressure among users (see section 9 in WARNINGS). Similar effects on risk factors have been associated with an increased risk of heart disease. Oral contraceptives must be used with caution in women with cardiovascular disease risk factors.


b. Thromboembolism

An increased risk of thromboembolic and thrombotic disease associated with the use of oral contraceptives is well established. Case control studies have found the relative risk of users compared to non-users to be 3 for the first episode of superficial venous thrombosis, 4 to 11 for deep vein thrombosis or pulmonary embolism, and 1.5 to 6 for women with predisposing conditions for venous thromboembolic disease (9,10,25-30).


Cohort studies have shown the relative risk to be somewhat lower, about 3 for new cases and about 4.5 for new cases requiring hospitalization (31). The risk of thromboembolic disease due to oral contraceptives is not related to length of use and disappears after pill use is stopped (8).


A two- to four-fold increase in relative risk of postoperative thromboembolic complications has been reported with the use of oral contraceptives (15,32). The relative risk of venous thrombosis in women who have predisposing conditions is twice that of women without such medical conditions (15,32). If feasible, oral contraceptives should be discontinued at least four weeks prior to and for two weeks after elective surgery of a type associated with an increase in risk of thromboembolism and during and following prolonged immobilization. Since the immediate postpartum period is also associated with an increased risk of thromboembolism, oral contraceptives should be started no earlier than four to six weeks after delivery in women who elect not to breast-feed.


c. Cerebrovascular Disease

Oral contraceptives have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes), although, in general, the risk is greatest among older (>35 years), hypertensive women who also smoke. Hypertension was found to be a risk factor for both users and nonusers, for both types of strokes, while smoking interacted to increase the risk for hemorrhagic strokes (33-35).


In a large study, the relative risk of thrombotic strokes has been shown to range from 3 for normotensive users to 14 for users with severe hypertension (36). The relative risk of hemorrhagic stroke is reported to be 1.2 for non-smokers who used oral contraceptives, 2.6 for smokers who did not use oral contraceptives, 7.6 for smokers who used oral contraceptives, 1.8 for normotensive users, and 25.7 for users with severe hypertension (36). The attributable risk is also greater in older women (9).


d. Dose-Related Risk of Vascular Disease from Oral Contraceptives

A positive association has been observed between the amount of estrogen and progestogen in oral contraceptives and the risk of vascular disease (37-39). A decline in serum high-density lipoproteins (HDL) has been reported with many progestational agents (20-22). A decline in serum high-density lipoproteins has been associated with an increased incidence of ischemic heart disease. Because estrogens increase HDL cholesterol, the net effect of an oral contraceptive depends on a balance achieved between doses of estrogen and progestin and the nature of the progestin used in the contraceptives. The amount and activity of both hormones should be considered in the choice of an oral contraceptive.


Minimizing exposure to estrogen and progestogen is in keeping with good principles of therapeutics. For any particular oral contraceptive, the dosage regimen prescribed should be one which contains the least amount of estrogen and progestogen that is compatible with the needs of the individual patient. New acceptors of oral contraceptive agents should be started on preparations containing the lowest dose of estrogen which produces satisfactory results for the patient.


e. Persistence of Risk of Vascular Disease

There are two studies which have shown persistence of risk of vascular disease for ever-users of oral contraceptives. In a study in the United States, the risk of developing myocardial infarction after discontinuing oral contraceptives persists for at least 9 years for women 40 to 49 years who had used oral contraceptives for 5 or more years, but this increased risk was not demonstrated in other age groups (14). In another study in Great Britain, the risk of developing cerebrovascular disease persisted for at least 6 years after discontinuation of oral contraceptives, although excess risk was very small (40). However, both studies were performed with oral contraceptive formulations containing 50 mcg or higher of estrogens.



2. Estimates of Mortality from Contraceptive Use


One study gathered data from a variety of sources which have estimated the mortality rate associated with different methods of contraception at different ages (Table III). These estimates include the combined risk of death associated with contraceptive methods plus the risk attributable to pregnancy in the event of method failure. Each method of contraception has its specific benefits and risks. The study concluded that with the exception of oral contraceptive users 35 and older who smoke and 40 and older who do not smoke, mortality associated with all methods of birth control is low and below that associated with childbirth. The observation of a possible increase in risk of mortality with age for oral contraceptive users is based on data gathered in the 1970's--but not reported until 1983 (41). However, current clinical practice involves the use of lower estrogen dose formulations combined with careful restriction of oral contraceptive use to women who do not have the various risk factors listed in this labeling.


Because of these changes in practice and, also, because of some limited new data which suggest that the risk of cardiovascular disease with the use of oral contraceptives may now be less than previously observed (Porter JB, Hunter J, Jick H, et al. Oral contraceptives and nonfatal vascular disease. Obstet Gynecol 1985;66:1-4 and Porter JB, Hershel J, Walker AM. Mortality among oral contraceptive users.


Obstet Gynecol 1987;70:29-32), the Fertility and Maternal Health Drugs Advisory Committee was asked to review the topic in 1989. The Committee concluded that although cardiovascular disease risks may be increased with oral contraceptive use after age 40 in healthy non-smoking women (even with the newer low-dose formulations), there are greater potential health risks associated with pregnancy in older women and with the alternative surgical and medical procedures which may be necessary if such women do not have access to effective and acceptable means of contraception.


Therefore, the Committee recommended that the benefits of oral contraceptive use by healthy non-smoking women over 40 may outweigh the possible risks. Of course, older women, as all women who take oral contraceptives, should take the lowest possible dose formulation that is effective.






























































TABLE III ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED DEATHS ASSOCIATED WITH CONTROL OF FERTILITY PER 100,000 NONSTERILE WOMEN, BY FERTILITY CONTROL METHOD ACCORDING TO AGE
Adapted from H.W. Ory, Reference 41

*

Deaths are birth related.

†

Deaths are method related.

Method of control and outcome15-1920-2425-2930-3435-3940-44
No fertility control methods*7.07.49.114.825.728.2
Oral contraceptives non-smoker†0.30.50.91.913.831.6
Oral contraceptives smoker†2.23.46.613.551.1117.2
IUD†0.80.81.01.01.41.4
Condom*1.11.60.70.20.30.4
Diaphragm/spermicide*1.91.21.21.32.22.8
Periodic abstinence*2.51.61.61.72.93.6

3. Carcinoma of the Reproductive Organs


Numerous epidemiological studies have been performed on the incidence of breast, endometrial, ovarian, and cervical cancer in women using oral contraceptives. Most of the studies on breast cancer and oral contraceptive use report that the use of oral contraceptives is not associated with an increase in the risk of developing breast cancer (42,44,89). Some studies have reported an increased risk of developing breast cancer in certain subgroups of oral contraceptive users, but the findings reported in these studies are not consistent (43,45-49,85-88).


Some studies suggest that oral contraceptive use has been associated with an increase in the risk of cervical intraepithelial neoplasia in some populations of women (51-54). However, there continues to be controversy about the extent to which such findings may be due to differences in sexual behavior and other factors.


In spite of many studies of the relationship between oral contraceptive use and breast and cervical cancers, a cause and effect relationship has not been established.



4. Hepatic Neoplasia


Benign hepatic adenomas are associated with oral contraceptive use, although the incidence of benign tumors is rare in the United States.


Indirect calculations have estimated the attributable risk to be in the range of 3.3 cases/100,000 for users, a risk that increases after four or more years of use (55). Rupture of rare, benign, hepatic adenomas may cause death through intra-abdominal hemorrhage (56,57).


Studies from Britain have shown an increased risk of developing hepatocellular carcinoma (58-60) in long-term (>8 years) oral contraceptive users. However, these cancers are extremely rare in the U.S., and the attributable risk (the excess incidence) of liver cancers in oral contraceptive users approaches less than one per million users.



5. Ocular Lesions


There have been clinical case reports of retinal thrombosis associated with the use of oral contraceptives. Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions. Appropriate diagnostic and therapeutic measures should be undertaken immediately.



6. Oral Contraceptive Use Before or During Early Pregnancy


Extensive epidemiological studies have revealed no increased risk of birth defects in women who have used oral contraceptives prior to pregnancy (61-63). Studies also do not suggest a teratogenic effect, particularly insofar as cardiac anomalies and limb reduction defects are concerned (61,62,64,65), when taken inadvertently during early pregnancy.


The administration of oral contraceptives to induce withdrawal bleeding should not be used as a test for pregnancy. Oral contraceptives should not be used during pregnancy to treat threatened or habitual abortion.


It is recommended that for any patient who has missed two consecutive periods, pregnancy should be ruled out before continuing oral contraceptive use. If the patient has not adhered to the prescribed schedule, the possibility of pregnancy should be considered at the time of the first missed period. Oral contraceptive use should be discontinued if pregnancy is confirmed.



7. Gallbladder Disease


Earlier studies have reported an increased lifetime relative risk of gallbladder surgery in users of oral contraceptives and estrogens (66,67).


More recent studies, however, have shown that the relative risk of developing gallbladder disease among oral contraceptive users may be minimal (68-70). The recent findings of minimal risk may be related to the use of oral contraceptive formulations containing lower hormonal doses of estrogens and progestogens.



8. Carbohydrate and Lipid Metabolic Effects


Oral contraceptives have been shown to cause glucose intolerance in a significant percentage of users (23). Oral contraceptives containing greater than 75 mcg of estrogens cause hyperinsulinism, while lower doses of estrogen cause less glucose intolerance (71).


Progestogens increase insulin secretion and create insulin resistance, this effect varying with different progestational agents (23,72).


However, in the non-diabetic woman, oral contraceptives appear to have no effect on fasting blood glucose (73). Because of these demonstrated effects, prediabetic and diabetic women should be carefully observed while taking oral contraceptives.


A small proportion of women will have persistent hypertriglyceridemia while on the pill. As discussed earlier (see WARNINGS, 1a. and 1d.), changes in serum triglycerides and lipoprotein levels have been reported in oral contraceptive users.



9. Elevated Blood Pressure


An increase in blood pressure has been reported in women taking oral contraceptives (74) and this increase is more likely in older oral contraceptive users (75) and with continued use (74). Data from the Royal College of General Practitioners (18) and subsequent randomized trials have shown that the incidence of hypertension increases with increasing concentrations of progestogens.


Women with a history of hypertension or hypertension-related diseases or renal disease (76) should be encouraged to use another method of contraception. If women elect to use oral contraceptives, they should be monitored closely, and if significant elevation of blood pressure occurs, oral contraceptives should be discontinued. For most women, elevated blood pressure will return to normal after stopping oral contraceptives (75), and there is no difference in the occurrence of hypertension among ever and never users (74,76,77).



10. Headache


The onset or exacerbation of migraine or development of headache with a new pattern which is recurrent, persistent, or severe requires discontinuation of oral contraceptives and evaluation of the cause.



11. Bleeding Irregularities


Breakthrough bleeding and spotting are sometimes encountered in patients on oral contraceptives, especially during the first three months of use. Non-hormonal causes should be considered, and adequate diagnostic measures taken to rule out malignancy or pregnancy in the event of breakthrough bleeding, as in the case of any abnormal vaginal bleeding. If pathology has been excluded, time or a change to another formulation may solve the problem. In the event of amenorrhea, pregnancy should be ruled out.


Some women may encounter post-pill amenorrhea or oligomenorrhea, especially when such a condition was preexistent.


Precautions

1. Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted diseases.



2. Physical Examination and Follow-Up


It is good medical practice for all women to have annual history and physical examinations, including women using oral contraceptives.


The physical examination, however, may be deferred until after initiation of oral contraceptives if requested by the woman and judged appropriate by the clinician. The physical examination should include special reference to blood pressure, breasts, abdomen and pelvic organs, including cervical cytology, and relevant laboratory tests. In case of undiagnosed, persistent or recurrent abnormal vaginal bleeding, appropriate measures should be conducted to rule out malignancy. Women with a strong family history of breast cancer or who have breast nodules should be monitored with particular care.



3. Lipid Disorders


Women who are being treated for hyperlipidemia should be followed closely if they elect to use oral contraceptives. Some progestogens may elevate LDL levels and may render the control of hyperlipidemias more difficult.



4. Liver Function


If jaundice develops in any woman receiving such drugs, the medication should be discontinued. Steroid hormones may be poorly metabolized in patients with impaired liver function.



5. Fluid Retention


Oral contraceptives may cause some degree of fluid retention. They should be prescribed with caution, and only with careful monitoring, in patients with conditions which might be aggravated by fluid retention.



6. Emotional Disorders


Women with a history of depression should be carefully observed and the drug discontinued if depression recurs to a serious degree.



7. Contact Lenses


Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.



8. Drug Interactions



Effects of Other Drugs on Oral Contraceptives (78)


Rifampin:

Metabolism of both norethindrone and ethinyl estradiol is increased by rifampin. A reduction in contraceptive effectiveness and increased incidence of breakthrough bleeding and menstrual irregularities have been associated with concomitant use of rifampin.


Anticonvulsants:

 Anticonvulsants such as phenobarbital, phenytoin, and carbamazepine, have been shown to increase the metabolism of ethinyl estradiol and/or norethindrone, which could result in a reduction in contraceptive effectiveness.


Troglitazone:

Administration of troglitazone with an oral contraceptive containing ethinyl estradiol and norethindrone reduced the plasma concentrations of both by approximately 30%, which could result in a reduction in contraceptive effectiveness.


Antibiotics:

Pregnancy while taking oral contraceptives has been reported when the oral contraceptives were administered with antimicrobials such as ampicillin, tetracycline, and griseofluvin. However, clinical pharmacokinetic studies have not demonstrated any consistent effect of antibiotics (other than rifampin) on plasma concentrations of synthetic steroids.


Atorvastatin:

Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%, respectively.


Other:

Ascorbic acid and acetaminophen may increase plasma ethinyl estradiol concentrations, possibly by inhibition of conjugation. A reduction in contraceptive effectiveness and increased incidence of breakthrough bleeding has been suggested with phenylbutazone.



Effects of Oral Contraceptives on Other Drugs


Oral contraceptive combinations containing ethinyl estradiol may inhibit the metabolism of other compounds. Increased plasma concentrations of cyclosporine, prednisolone, and theophylline have been reported with concomitant administration of oral contraceptives. In addition, oral contraceptives may induce the conjugation of other compounds. Decreased plasma concentrations of acetaminophen and increased clearance of temazepam, salicylic acid, morphine, and clofibric acid have been noted when these drugs were administered with oral contraceptives.



9. Interactions with Laboratory Tests


Certain endocrine and liver function tests and blood components may be affected by oral contraceptives:





        1. Increased prothrombin and factors VII, VIII, IX, and X; decreased antithrombin 3; increased norepinephrine-induced platelet aggregability.

        2. Increased thyroid binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (PBI), T4 by column or by radioimmunoassay. Free T3 resin uptake is decreased, reflecting the elevated TBG; free T4 concentration is unaltered.

        3. Other binding proteins may be elevated in serum.

        4. Sex-binding globulins are increased and result in elevated levels of total circulating sex steroids and corticoids; however, free or biologically active levels remain unchanged.

        5. Triglycerides may be increased.

        6. Glucose tolerance may be decreased.

        7. Serum folate levels may be depressed by oral contraceptive therapy. This may be of clinical significance if a woman becomes pregnant shortly after discontinuing oral contraceptives.





10. Carcinogenesis


See WARNINGS section.



11. Pregnancy


Pregnancy Category X: See CONTRAINDICATIONS and WARNINGS sections.



12. Nursing Mothers


Small amounts of oral contraceptive steroids have been identified in the milk of nursing mothers, and a few adverse effects on the child have been reported, including jaundice and breast enlargement. In addition, oral contraceptives, given in the postpartum period may interfere with lactation by decreasing the quantity and quality of breast milk. If possible, the nursing mother should be advised not to use oral contraceptives but to use other forms of contraception until she has completely weaned her child.



13. Pediatric Use


Safety and efficacy of norethindrone acetate and ethinyl estradiol tablets have been established in women of reproductive age. Safety and efficacy are expected to be the same for postpubertal adolescents under the age of 16 and for users 16 years and older. Use of this product before menarche is not indicated.



INFORMATION FOR THE PATIENT


See patient labeling printed below.



Adverse Reactions


An increased risk of the following serious adverse reactions has been associated with the use of oral contraceptives (see WARNINGS section):


  • Thrombophlebitis

  • Arterial thromboembolism

  • Pulmonary embolism

  • Myocardial infarction

  • Cerebral hemorrhage

  • Cerebral thrombosis

  • Hypertension

  • Gallbladder disease

  • Hepatic adenomas or benign liver tumors

There is evidence of an association between the following conditions and the use of oral contraceptives, although additional confirmatory studies are needed:


  • Mesenteric thrombosis

  • Retinal thrombosis

The following adverse reactions have been reported in patients receiving oral contraceptives and are believed to be drug-related:


  • Nausea

  • Vomiting

  • Gastrointestinal symptoms (such as abdominal cramps and bloating)

  • Breakthrough bleeding

  • Spotting

  • Change in menstrual flow

  • Amenorrhea

  • Temporary infertility after discontinuation of treatment

  • Edema

  • Melasma which may persist

  • Breast changes: tenderness, enlargement, secretion

  • Change in weight (increase or decrease)

  • Change in cervical erosion and secretion

  • Diminution in lactation when given immediately postpartum

  • Cholestatic jaundice

  • Migraine

  • Rash (allergic)

  • Mental depression

  • Reduced tolerance to carbohydrates

  • Vaginal candidiasis

  • Change in corneal curvature (steepening)

  • Intolerance to contact lenses

The following adverse reactions have been reported in users of oral contraceptives and the association has been neither confirmed nor refuted:


  • Pre-menstrual syndrome

  • Cataracts

  • Changes in appetite

  • Cystitis-like syndrome

  • Headache

  • Nervousness

  • Dizziness

  • Hirsutism

  • Loss of scalp hair

  • Erythema multiforme

  • Erythema nodosum

  • Hemorrhagic eruption

  • Vaginitis

  • Porphyria

  • Impaired renal function

  • Hemolytic uremic syndrome

  • Budd-Chiari syndrome

  • Acne

  • Changes in libido

  • Colitis


Overdosage


Serious ill effects have not been reported following acute ingestion of large doses of oral contraceptives by young children. Overdosage may cause nausea, and withdrawal bleeding may occur in female

Sibutramine Hydrochloride


Class: Anorexigenic Agents and Respiratory and Cerebral Stimulants, Miscellaneous
VA Class: GA751
Chemical Name: 1-(4-chlorophenyl)-N,N-dimethyl-α-(2-methylpropyl)-cyclobutanemethanamine hydrochloride monohydrate
Molecular Formula: C17H26ClN • HCl • H2O
CAS Number: 84485-00-7
Brands: Meridia


Special Alerts:


On October 8, 2010, the manufacturer announced a voluntary withdrawal of sibutramine from the US market.19 20 The withdrawal was requested by FDA following review of new data on cardiovascular risk.19 20 (See Cardiovascular Effects under Cautions.)


REMS:


FDA approved a REMS for sibutramine to ensure that the benefits of a drug outweigh the risks. The REMS may apply to one or more preparations of sibutramine and consists of the following: medication guide. See the FDA REMS page () or the ASHP REMS Resource Center ().



Introduction

Anorexigenic agent.1 4 7 9


Uses for Sibutramine Hydrochloride


Obesity


Adjunct to caloric restriction, increased physical activity, and behavioral modification in the management of exogenous obesity; used for weight loss and maintenance of weight loss.1 4 7 9 (See Special Alerts.)


Used in patients with initial body mass index (BMI) of ≥30 kg/m2; also used in those with BMI of ≥27 kg/m2 in the presence of risk factor or disease (e.g., adequately controlled hypertension, diabetes mellitus, dyslipidemia).1 4 7


Effect of sibutramine on the morbidity and mortality associated with obesity not established.1 2


Sibutramine Hydrochloride Dosage and Administration


General



  • Allow at least 2 weeks to elapse between discontinuance of an MAO inhibitor and initiation of sibutramine and vice versa.1 7



Administration


Oral Administration


Administer orally without regard to meals.1


Administered once daily in the morning in clinical studies.1


Dosage


Available as sibutramine hydrochloride monohydrate; dosage expressed in terms of the monohydrate.1 10


Adults


Obesity

Oral

Initially, 10 mg once daily.1


If weight loss is inadequate (e.g., <1.8 kg of weight loss) after 4 weeks of treatment, consider increasing dosage to 15 mg daily or discontinuance; take BP and heart rate into account.1 7


If weight loss during the first 3–6 months of therapy is <5% of the patient’s baseline body weight, FDA recommends discontinuance, since continued sibutramine therapy is unlikely to be effective and would expose the patient to unnecessary risks.17


Reserve 5-mg daily dose for patients who do not tolerate 10 mg daily.1


Safety and efficacy >2 years not established in clinical studies.1


Prescribing Limits


Adults


Obesity

Oral

Maximum 15 mg daily.1


Special Populations


Hepatic Impairment


Mild or moderate hepatic impairment: Dosage adjustment not needed.1 (See Special Populations under Pharmacokinetics.) Not recommended in severe hepatic impairment.1


Renal Impairment


Not recommended in severe renal impairment.1


Geriatric Patients


Contraindicated in patients >65 years of age.1


Cautions for Sibutramine Hydrochloride


Contraindications



  • History of CAD (e.g., angina, history of MI), CHF, tachycardia, peripheral arterial occlusive disease, cardiac arrhythmia, or cerebrovascular disease (stroke or TIA).1 (See Cardiovascular Effects under Cautions.)




  • Inadequately controlled hypertension (systolic/diastolic BP >145/90 mm Hg).1 (See Cardiovascular Effects under Cautions.)




  • Geriatric patients >65 years of age.1




  • Concurrent or recent (i.e., within 2 weeks) therapy with an MAO inhibitor.1 (See Drug Interactions under Cautions.)




  • Major eating disorder (e.g., anorexia nervosa, bulimia nervosa).1




  • Concurrent therapy with another centrally acting anorexigenic drug.1 (See Specific Drugs under Interactions.)




  • Known hypersensitivity to sibutramine or any ingredient in the formulation.1



Warnings/Precautions


Warnings


Cardiovascular Effects

Substantially increases BP and increases pulse in some patients, particularly when initiated at higher dosages.1 9 Monitoring of BP and pulse required prior to and at regular intervals during therapy.1 7 Consideration of decreased dosage or discontinuance recommended in patients with sustained increases in BP or pulse rate.1 7


Caution in patients with a history of hypertension.1 Should not be used in those with uncontrolled or poorly controlled hypertension.1


Contraindicated in patients with history of CAD (e.g., angina, history of MI), CHF, tachycardia, peripheral arterial occlusive disease, cardiac arrhythmia, or cerebrovascular disease (stroke or TIA).1


Increased risk of nonfatal MI and stroke reported in overweight or obese patients at increased risk for cardiovascular events (≥55 years of age, history of cardiovascular disease [CAD, peripheral arterial occlusive disease, or stroke] and/or type 2 diabetes mellitus, and ≥1 additional cardiovascular risk factor); effects on body weight relative to placebo were modest.15 16 17 19 21 FDA concluded that the modest increase in weight loss, in the absence of evidence of other associated health benefits, would be outweighed by even a small increase in risk of cardiovascular events.21 22 19 On October 8, 2010, the manufacturer voluntarily complied with FDA's request to voluntarily withdraw sibutramine from the US market.19 20


Health care professionals should stop prescribing and dispensing sibutramine and should contact patients currently taking the drug to inform them of the risks and advise them to stop taking the drug.19 Individuals receiving sibutramine therapy should stop taking the drug and discuss alternatives for weight loss or weight-loss maintenance with their clinician.19


Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-like Reactions

Potentially life-threatening serotonin syndrome or NMS-like reactions reported during concurrent therapy with SSRIs or SNRIs and other serotonergic drugs (e.g., 5-HT1 receptor agonists [“triptans”]), drugs that impair serotonin metabolism (e.g., MAO inhibitors), or antipsychotics or other dopamine antagonists.1 (See Contraindications under Cautions and see Specific Drugs under Interactions.)


Symptoms of serotonin syndrome may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile BP, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination), and/or GI symptoms (e.g., nausea, vomiting, diarrhea).1


Severe serotonin syndrome may resemble NMS, which is characterized by hyperthermia, muscle rigidity, autonomic instability with possible rapid fluctuation of vital signs, and mental status changes.1


Monitor patients receiving sibutramine for the development of serotonin syndrome or NMS-like signs and symptoms.1 Serotonin syndrome requires immediate medical treatment.1


Drug Interactions

Concomitant use with MAO inhibitor associated with serotonin syndrome.1 7 (See Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-like Reactions under Cautions and see Specific Drugs under Interactions.)


Glaucoma

May cause mydriasis; caution in patients with angle-closure (narrow-angle) glaucoma.1


Other Warnings

Exclude organic causes (e.g., untreated hypothyroidism) of obesity before initiating sibutramine.1


General Precautions


Pulmonary Hypertension

Pulmonary hypertension associated with anorexigenic drugs that induce serotonin release; risk with sibutramine unknown.1


Seizures

Seizures reported rarely.1 Caution in patients with history of seizures; discontinue if seizures occur.1 6


Bleeding

Bleeding events reported; causal relationship unclear.1 Caution in patients predisposed to bleeding and in those receiving drugs that affect hemostasis or platelet function.1


Cholelithiasis

Weight loss can exacerbate or precipitate gallstone formation.1


CNS Effects

Like other CNS-active drugs, may impair judgment, thinking, or motor skills.1


Specific Populations


Pregnancy

Category C.1 Use during pregnancy not recommended.1


Lactation

Not known whether sibutramine is distributed into milk.1 Use not recommended.1


Pediatric Use

Safety and efficacy in children <16 years of age not established.1


In one clinical study in obese adolescents, 2 patients reported suicidal ideation and one patient attempted suicide.1 Sibutramine inhibits reuptake of serotonin and norepinephrine similarly to the mechanism of some antidepressants; not known whether the drug increases the risk of suicidality in pediatric patients.1


Geriatric Use

Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults; contraindicated in patients >65 years of age.1


Hepatic Impairment

Use not recommended in patients with severe hepatic impairment; not systematically evaluated in these individuals.1


Renal Impairment

Do not use in patients with severe renal impairment, including those with end-stage renal disease receiving dialysis.1 Use with caution in patients with mild or moderate renal impairment.1


Common Adverse Effects


Headache, dry mouth, anorexia, constipation, insomnia, rhinitis, pharyngitis, increased appetite, back pain, flu syndrome, accidental injury, asthenia, nausea, arthralgia, nervousness, dyspepsia, sinusitis.1 7 9


Interactions for Sibutramine Hydrochloride


Metabolized to active metabolites principally by CYP3A4.1 7


Drugs Affecting Hepatic Microsomal Enzymes


Pharmacokinetic interaction likely with drugs that inhibit CYP3A4 with possible alteration in the metabolism of sibutramine.1


Drugs Affecting Hemostasis or Platelet Function.


Possible increased risk of bleeding; caution advised.1


Protein-bound Drugs


Interaction unlikely.1


Specific Drugs













































Drug



Interaction



Comments



Alcohol



Pharmacologic interaction unlikely1 7


No clinically important psychomotor interactions reported in limited study1



Excessive alcohol consumption not recommended1 7



Cimetidine



Small increases in AUC and peak plasma concentrations of sibutramine metabolites1 7



CNS drugs



Potential pharmacologic interaction1



Caution advised1 7



Erythromycin



Decreased sibutramine metabolism; altered serum concentrations of sibutramine and its metabolites1 7



Ketoconazole



Decreased sibutramine metabolism; altered serum concentrations of sibutramine and its metabolites1 7



Lorazepam



No significant changes in pharmacokinetics of active sibutramine metabolites or lorazepam1



MAO inhibitors (e.g., phenelzine, selegiline)



Potentially fatal serotonin syndrome1 7



Concomitant use contraindicated1


Allow at least 2 weeks to elapse between discontinuance of the MAO inhibitor and initiation of sibutramine and vice versa1 7



Olanzapine



Increased peak plasma concentration and AUC of sibutramine and increased peak plasma concentration of its active secondary metabolite; no significant effect on olanzapine pharmacokinetics1



Omeprazole



Increased peak plasma concentration and AUC of sibutramine and its active secondary metabolite; no significant effect on omeprazole pharmacokinetics1



Oral contraceptives



Suppression of ovulation not inhibited1



Alternative contraceptive precautions not needed1 7



Serotonergic drugs (dihydroergotamine, lithium, opiate agonists [e.g., dextromethorphan, fentanyl, meperidine, pentazocine], sumatriptan, tryptophan, serotonin-reuptake inhibitors)



Potential for serotonin syndrome; potentially serious or fatal1 7



Sibutramine should not be used with other serotonergic agents; if such use is clinically indicated, monitor carefully1 7



Simvastatin



Decreased peak plasma concentrations and AUC of sibutramine and its active secondary metabolite; increased simvastatin acid AUC1



Sympathomimetic agents (ephedrine, pseudoephedrine)



Potential pharmacologic interaction with drugs that may increase BP and pulse1 7



Caution1 7


Sibutramine Hydrochloride Pharmacokinetics


Absorption


Bioavailability


Rapidly absorbed from the GI tract; undergoes extensive first-pass hepatic metabolism to active mono- and di-desmethyl metabolites (M1, M2).1


77% of a single oral dose is absorbed; absolute bioavailability undetermined.1


Food


Food reduces peak plasma concentrations of M1 and M2 by 27 and 32%, respectively, and delays time to peak plasma concentrations by about 3 hours but does not affect AUCs of M1 or M2.1


Special Populations


Geriatric patients: Plasma concentrations of M1 and M2 metabolites are similar to those in younger adults.1


Moderate hepatic impairment: Combined AUCs of M1 and M2 metabolites increased by 24% compared with values in healthy individuals.1


Moderate or severe renal impairment: AUC of M1 metabolite increased by 24–46% compared with values in healthy individuals.1 End-stage renal disease: AUC of M2 metabolite decreased by 50% in patients receiving dialysis compared with values in healthy individuals.1 AUCs of inactive M5 and M6 metabolites increased twofold to threefold or eightfold to 11-fold in patients with moderate or severe renal impairment, respectively, and increased 22- to 33-fold in those with end-stage renal disease receiving dialysis compared with values in healthy individuals.1


Distribution


Extent


Extensively distributed, highest concentration in liver and kidney.1


Plasma Protein Binding


Sibutramine: 97%.1


M1 and M2: 94% each.1


Elimination


Metabolism


Principally metabolized in the liver by CYP3A4 to active mono-desmethyl (M1) and di-desmethyl (M2) metabolites; then hydroxylated and conjugated to inactive metabolites (M5 and M6).1


Elimination Route


Excreted principally in urine (77%) as inactive metabolites and in feces.1


Half-life


Sibutramine: 1.1 hours.1


M1: 14 hours.1


M2: 16 hours.1


Stability


Storage


Oral


Capsules

25°C (may be exposed to 15–30°C).1 Protect from heat and moisture.1


Actions



  • Anorectic effects principally due to active metabolites (M1 and M2) that inhibit reuptake (but not release) of serotonin, norepinephrine, and, to a lesser extent, dopamine at the neuronal synapse, thus promoting a sense of satiety.1 2 3 7 9




  • Increase energy expenditure through thermogenic effects in animals: not confirmed in humans.3 7 10



Advice to Patients



  • Importance of reading the manufacturer’s patient information (medication guide) prior to beginning therapy and rereading it each time the prescription is renewed.1




  • Importance of informing clinician of the presence of, or any history of, cardiovascular disease, including CAD (e.g., angina, MI), CHF, tachycardia, peripheral arterial occlusive disease, cardiac arrhythmia, or cerebrovascular disease (stroke, TIA).6 Importance of informing clinician of any other concomitant disease (e.g., glaucoma, seizures, high BP, major eating disorder).6




  • Importance of immediately informing clinician if any signs or symptoms suggestive of cardiovascular disease (e.g., chest pain, palpitation, abnormal heart rate or rhythm) occur.19




  • Importance of notifying clinician if rash, urticaria, or other manifestations of allergic reaction occur.1




  • Importance of monitoring BP and pulse at regular intervals.1




  • Importance of not taking an extra dose if one is missed.6




  • Importance of informing clinician of existing or contemplated concomitant therapy, including prescription or OTC drugs, especially other drugs for promoting weight loss, decongestants, antidepressants, cough suppressants, lithium, dihydroergotamine, sumatriptan, or tryptophan because of potential for interactions.1




  • Potential for sibutramine to impair judgment, thinking, or motor skills; avoid driving or operating machinery until effects on the individual are known.1 6




  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1




  • Importance of informing patients of other important precautionary information.1 (See Cautions.)



Preparations


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.


On October 8, 2010, the manufacturer announced a voluntary withdrawal of sibutramine from the US market.20 (See Cardiovascular Effects under Cautions.)























Sibutramine Hydrochloride

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Oral



Capsules



5 mg



Meridia (C-IV)



Abbott



10 mg



Meridia (C-IV)



Abbott



15 mg



Meridia (C-IV)



Abbott



Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.


The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions October 27, 2011. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.




References



1. Abbott. Meridia (sibutramine hydrochloride monohydrate) capsules prescribing information. North Chicago, IL; 2010 Aug.



2. Anon. Sibutramine for obesity. Med Lett Drugs Ther. 1998; 40:32. [PubMed 9529518]



3. Stock MJ. Sibutramine: a review of the pharmacology of a novel anti-obesity agent. Int J Obes Relat Metab Disord. 1997; 21(Suppl 1):S25-29. [PubMed 9130038]



4. National Institutes of Health, National Heart, Lung, and Blood Institute. Clinical Guidelines on the identification, evaluation and treatment of overweight and obesity in adults. The evidence report. Bethesda, MD; June 1998. From NHLBI web site.



5. Anon. American Heart Association urges caution on new diet drug. American Heart Association media advisory. Dallas, TX; 1997.



6. Abbott. Meridia (sibutramine hydrochloride monohydrate) capsules patient information. North Chicago, IL; 2010 Jan.



7. Luque CA, Rey JA. Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Ann Pharmacother. 1999; 33:968-78. [IDIS 436183] [PubMed 10492502]



8. Smith IG, Goulder MA. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract. 2001; 50:505-12. [PubMed 11407998]



9. Lean ME. Sibutramine—a review of clinical efficacy. Int J Obesity. 1997; 21:S30-6.



10. Abbott, Abbott Park, IL: Personal communication.



11. Baumgarten AH (US Food and Drug Administration Chicago District Office, Chicago, IL): Personal communication to White M (Abbott Laboratories, Abbott Park, IL); 2002 Jul 19.



12. Wolfe SH, Sasich LD, Barbehenn E (Public Citizen Health Research Group, Washington, DC): Personal communication to Thompson T (US Department of Health and Human Services, Washington DC); 2002 Mar 19.



13. Sun E (Abbott Laboratories, Abbott Park, IL): Personal communication to Thompson T (US Department of Health and Human Services, Washington DC); 2002 Jun 4.



15. James WPT. The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients. Eur Heart J. 2005; 7(suppl L):L44-8.



16. Torp-Pedersen C, Caterson I, Coutinho W et al. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J. 2007; 28:2915-23. [PubMed 17595194]



17. Food and Drug Administration. Follow-up to the November 2009 early communication about an ongoing safety review of sibutramine, marketed as Meridia. Rockville, MD; 2010 Jan 21. From FDA website.



18. Food and Drug Administration. Early communication about an ongoing safety review of Meridia (sibutramine hydrochloride), Rockville, MD; 2009 Nov 20. From FDA website.



19. Food and Drug Administration. Drug safety communication: FDA recommends against the continued use of Meridia (sibutramine). Rockville, MD; 2010 Oct 8. From FDA website.



20. Abbott. Abbott to voluntarily withdraw Meridia (sibutramine) in the U.S. Abbott Park, IL; 2010 Oct 8. Press release from Abbott website.



21. Egan AG, Avigan M. Memorandum to the file, NDA 20-632, Meridia (sibutramine hydrochloride monohydrate). Rockville, MD: Food and Drug Administration; 2010 Oct 4. From FDA website.



22. Food and Drug Administration. Questions and answers: FDA recommends against the continued use of Meridia (sibutramine). Available from website. Accessed 2010 Oct 8.



More Sibutramine Hydrochloride resources


  • Sibutramine Hydrochloride Side Effects (in more detail)
  • Sibutramine Hydrochloride Dosage
  • Sibutramine Hydrochloride Use in Pregnancy & Breastfeeding
  • Sibutramine Hydrochloride Drug Interactions
  • Sibutramine Hydrochloride Support Group
  • 62 Reviews for Sibutramine Hydrochloride - Add your own review/rating


Compare Sibutramine Hydrochloride with other medications


  • Obesity

Saturday, 14 July 2012

Adriamycin


Generic Name: doxorubicin (Intravenous route)

dox-oh-ROO-bi-sin

Intravenous route(Solution;Powder for Solution)

Severe local tissue necrosis will occur if there is extravasation during administration; do not administer by the intramuscular or subcutaneous route. Myocardial toxicity manifested in its most severe form by potentially fatal congestive heart failure (CHF) may occur either during therapy or months to years after termination of therapy. The risk of developing CHF increases rapidly with increasing total cumulative doses of doxorubicin in excess of 400 mg/m(2). Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) have been reported in patients treated with anthracyclines. Pediatric patients are also at risk for developing secondary AML. Reduce dosage in patients with impaired hepatic function. Severe myelosuppression may occur with therapy .



Commonly used brand name(s)

In the U.S.


  • Adriamycin

Available Dosage Forms:


  • Powder for Solution

  • Solution

Therapeutic Class: Antineoplastic Agent


Chemical Class: Anthracycline


Uses For Adriamycin


Doxorubicin belongs to the general group of medicines known as antineoplastics. It is used to treat some kinds of cancers of the blood; lymph system; bladder; breast; stomach; lung; ovaries; thyroid; nerves; kidneys; bones; and soft tissues, including muscles and tendons. It may also be used to treat other kinds of cancer, as determined by your doctor.


Doxorubicin seems to interfere with the growth of cancer cells, which are then eventually destroyed by the body. Since the growth of normal body cells may also be affected by doxorubicin, other effects will also occur. Some of these may be serious and must be reported to your doctor. Other effects, like hair loss, may not be serious but may cause concern. Some effects may not occur until months or years after the medicine is used.


Before you begin treatment with doxorubicin, you and your doctor should talk about the good this medicine will do as well as the risks of using it.


Doxorubicin is to be administered only by or under the supervision of your doctor.


Once a medicine has been approved for marketing for a certain use, experience may show that it is also useful for other medical problems. Although these uses are not included in product labeling, doxorubicin is used in certain patients with the following medical conditions:


  • Autoimmune deficiency syndrome (AIDS)–associated Kaposi's sarcoma (a type of cancer of the skin and mucous membranes that is more common in patients with AIDS)

  • Cancer of the adrenal cortex (the outside layer of the adrenal gland)

  • Cancer of the cervix

  • Cancer of the endometrium

  • Cancer of the esophagus

  • Cancers of the head and neck

  • Cancer of the liver

  • Cancer of the pancreas

  • Cancer of the prostate

  • Cancer of the thymus (a small organ found under the breast bone)

  • Carcinoid tumors

  • Chronic lymphocytic leukemia (a type of cancer of the blood and lymph system)

  • Ewing's sarcoma (a type of cancer found in the bone)

  • Gestational trophoblastic tumors (tumors in the uterus or womb)

  • Hepatoblastoma (a certain type of liver cancer that occurs in children)

  • Multiple myeloma (a certain type of cancer of the blood)

  • Non–small cell lung cancer (a certain type of lung cancer usually associated with prior smoking, passive smoking, or radon exposure)

  • Retinoblastoma (a type of eye cancer found primarily in children)

  • Tumors in the ovaries

Before Using Adriamycin


In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:


Allergies


Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.


Pediatric


Heart problems are more likely to occur in children younger than 2 years of age, who are usually more sensitive to the effects of doxorubicin.


Geriatric


Heart problems are more likely to occur in the elderly, who are usually more sensitive to the effects of doxorubicin. The elderly may also be more likely to have blood problems.


Pregnancy








Pregnancy CategoryExplanation
All TrimestersDStudies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy in a life threatening situation or a serious disease, may outweigh the potential risk.

Breast Feeding


Studies in women breastfeeding have demonstrated harmful infant effects. An alternative to this medication should be prescribed or you should stop breastfeeding while using this medicine.


Interactions with Medicines


Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are receiving this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.


Using this medicine with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.


  • Rotavirus Vaccine, Live

Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Adenovirus Vaccine Type 4, Live

  • Adenovirus Vaccine Type 7, Live

  • Bacillus of Calmette and Guerin Vaccine, Live

  • Cisplatin

  • Clozapine

  • Docetaxel

  • Glucosamine

  • Influenza Virus Vaccine, Live

  • Measles Virus Vaccine, Live

  • Mumps Virus Vaccine, Live

  • Paclitaxel

  • Rotavirus Vaccine, Live

  • Rubella Virus Vaccine, Live

  • Smallpox Vaccine

  • Stavudine

  • Trastuzumab

  • Typhoid Vaccine

  • Valspodar

  • Varicella Virus Vaccine

  • Warfarin

  • Yellow Fever Vaccine

  • Zidovudine

Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Cyclosporine

  • Eltrombopag

  • Phenytoin

  • Sorafenib

Interactions with Food/Tobacco/Alcohol


Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.


Other Medical Problems


The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:


  • Chickenpox (including recent exposure) or

  • Herpes zoster (shingles)—Risk of severe disease affecting other parts of the body

  • Gout or

  • Kidney stones—Doxorubicin may increase levels of uric acid in the body, which can cause gout or kidney stones

  • Heart disease—Risk of heart problems caused by doxorubicin may be increased

  • Liver disease—Effects of doxorubicin may be increased because of its slower removal from the body

Proper Use of Adriamycin


Doxorubicin is sometimes given together with certain other medicines. If you are receiving a combination of medicines, it is important that you receive each one at the proper time. If you are taking some of these medicines by mouth, ask your health care professional to help you plan a way to take them at the right times.


While you are using this medicine, your doctor may want you to drink extra fluids so that you will pass more urine. This will help prevent kidney problems and keep your kidneys working well.


Doxorubicin often causes nausea and vomiting. However, it is very important that you continue to receive the medication, even if you begin to feel ill. Ask your health care professional for ways to lessen these effects.


Dosing


The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.


The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.


Precautions While Using Adriamycin


It is very important that your doctor check your progress at regular visits to make sure that this medicine is working properly and to check for unwanted effects.


While you are being treated with doxorubicin, and after you stop treatment with it, do not have any immunizations (vaccinations) without your doctor's approval. Doxorubicin may lower your body's resistance, and there is a chance you might get the infection the immunization is meant to prevent. In addition, other persons living in your household should not take oral polio vaccine, since there is a chance they could pass the polio virus on to you. Also, avoid persons who have taken oral polio vaccine within the last several months. Do not get close to them, and do not stay in the same room with them for very long. If you cannot take these precautions, you should consider wearing a protective face mask that covers the nose and mouth.


Doxorubicin can temporarily lower the number of white blood cells in your blood, increasing the chance of getting an infection. It can also lower the number of platelets, which are necessary for proper blood clotting. If this occurs, there are certain precautions you can take, especially when your blood count is low, to reduce the risk of infection or bleeding:


  • If you can, avoid people with infections. Check with your doctor immediately if you think you are getting an infection or if you get a fever or chills, cough or hoarseness, lower back or side pain, or painful or difficult urination.

  • Check with your doctor immediately if you notice any unusual bleeding or bruising; black, tarry stools; blood in urine or stools; or pinpoint red spots on your skin.

  • Be careful when using a regular toothbrush, dental floss, or toothpick. Your medical doctor, dentist, or nurse may recommend other ways to clean your teeth and gums. Check with your medical doctor before having any dental work done.

  • Do not touch your eyes or the inside of your nose unless you have just washed your hands and have not touched anything else in the meantime.

  • Be careful not to cut yourself when you are using sharp objects such as a safety razor or fingernail or toenail cutters.

  • Avoid contact sports or other situations where bruising or injury could occur.

If doxorubicin accidentally seeps out of the vein into which it is injected, it may damage some tissues and cause scarring. Tell the doctor or nurse right away if you notice redness, pain, or swelling at the place of injection.


Adriamycin Side Effects


Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.



Check with your doctor immediately if any of the following side effects occur:


Less common
  • Fast or irregular heartbeat

  • pain at place of injection

  • shortness of breath

  • swelling of feet and lower legs

Rare
  • Black, tarry stools

  • blood in urine

  • pinpoint red spots on skin

  • unusual bleeding or bruising

  • wheezing

Check with your doctor as soon as possible if any of the following side effects occur:


More common
  • Sores in mouth and on lips

Less common
  • Cough or hoarseness accompanied by fever or chills

  • darkening or redness of skin (if you recently had radiation treatment)

  • fever or chills

  • joint pain

  • lower back or side pain accompanied by fever or chills

  • painful or difficult urination accompanied by fever or chills

  • red streaks along injected vein

  • stomach pain

Rare
  • Skin rash or itching

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:


More common
  • Nausea and vomiting

Less common
  • Darkening of soles, palms, or nails

  • diarrhea

Doxorubicin causes the urine to turn reddish in color, which may stain clothes. This is not blood. It is to be expected and only lasts for 1 or 2 days after each dose is given.


This medicine often causes a temporary and total loss of hair. After treatment with doxorubicin has ended, normal hair growth should return.


After you stop using this medicine, it may still produce some side effects that need attention. During this period of time, check with your doctor immediately if you notice the following side effects:


  • Fast or irregular heartbeat

  • shortness of breath

  • swelling of feet and lower legs

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.


Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: Adriamycin side effects (in more detail)



The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.


The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.


More Adriamycin resources


  • Adriamycin Side Effects (in more detail)
  • Adriamycin Use in Pregnancy & Breastfeeding
  • Adriamycin Drug Interactions
  • Adriamycin Support Group
  • 1 Review for Adriamycin - Add your own review/rating


  • Adriamycin Prescribing Information (FDA)

  • Adriamycin MedFacts Consumer Leaflet (Wolters Kluwer)

  • Adriamycin Concise Consumer Information (Cerner Multum)

  • Doxorubicin Prescribing Information (FDA)

  • Doxorubicin Hydrochloride Monograph (AHFS DI)

  • Rubex Prescribing Information (FDA)



Compare Adriamycin with other medications


  • Acute Lymphoblastic Leukemia
  • Acute Myeloblastic Leukemia
  • Bladder Cancer
  • Breast Cancer
  • Cancer
  • Hodgkin's Lymphoma
  • Lung Cancer
  • Lymphoma
  • Multiple Myeloma
  • Neuroblastoma
  • Osteosarcoma
  • Ovarian Cancer
  • Soft Tissue Sarcoma
  • Stomach Cancer
  • Thyroid Cancer
  • Wilms' Tumor